0
Correspondence |

Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/β-Amyloid42 Ratio

Victoria Wong, MD
[+] Author Affiliations

Copyright 2007 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

More Author Information
Arch Neurol. 2007;64(9):1357-1357. doi:10.1001/archneur.64.9.1357-a
Text Size: A A A
Published online

Fagan and colleagues1 reported on the use of the CSF tau/Aβ42 ratio in predicting cognitive decline in nondemented older adults. Although they stated that participants in the study had no systemic medical illness that could contribute importantly to dementia, they made no mention of the participants' medication profiles.

Statins have been thought to play a role in preventing cognitive decline2 and possibly in altering CSF biomarkers3 among patients with Alzheimer disease (AD). In the preliminary results of a randomized controlled trial, the use of atorvastatin in patients with mild to moderate AD was shown to be beneficial in improving their cognitive scores on the Alzheimer's Disease Assessment Scale at 6 and 12 months.2 In addition, CSF levels of ptau were reduced among patients treated with simvastatin.3 These effects of statins could have been confounding factors in the results of the study by Fagan and colleagues.

Other common medications have also been suggested as possible treatments to slow the progression of AD. Medications that inhibit cyclooxygenase-1 such as indomethacin and diclofenac/misoprostol continue to be studied due to their anti-inflammatory effects.4 Patients with mild AD or MCI who received rosiglitazone were shown to exhibit better delayed recall and selective attention at 6 months.5 Administration of high-dose estradiol also significantly improved attention, verbal memory, and visual memory compared with placebo among postmenopausal women with AD.6

Because the use of statins, nonsteroidal anti-inflammatory drugs, thiazolidinediones, and estrogen is so ubiquitous among patients in the 60- to 91-year-old demographic that Fagan and colleagues studied, the profile of medication use among the study participants would be quite relevant in determining the validity of the study results.

AUTHOR INFORMATION

Correspondence: Dr Wong, John A. Burns School of Medicine, University of Hawaii, PO Box 23377, Honolulu, HI 96823 (wongvict@hawaii.edu).

Financial Disclosure: None reported.

REFERENCES

Fagan  AM, Roe  CM, Xiong  C, Mintun  MA, Morris  JC, Holtzman  DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64 (3) 343- 349
PubMed
Sparks  DL, Sabbagh  MN, Connor  DJ.  et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62 (5) 753- 757
PubMed
Riekse  RG, Li  G, Petrie  EC.  et al.  Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 2006;10 (4) 399- 406
PubMed
McGeer  PL, McGeer  EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28 (5) 639- 647
PubMed
Watson  GS, Cholerton  BA, Reger  MA.  et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13 (11) 950- 958
PubMed
Asthana  S, Baker  LD, Craft  S.  et al.  High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57 (4) 605- 612
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Fagan  AM, Roe  CM, Xiong  C, Mintun  MA, Morris  JC, Holtzman  DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64 (3) 343- 349
PubMed
Sparks  DL, Sabbagh  MN, Connor  DJ.  et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005;62 (5) 753- 757
PubMed
Riekse  RG, Li  G, Petrie  EC.  et al.  Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 2006;10 (4) 399- 406
PubMed
McGeer  PL, McGeer  EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007;28 (5) 639- 647
PubMed
Watson  GS, Cholerton  BA, Reger  MA.  et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13 (11) 950- 958
PubMed
Asthana  S, Baker  LD, Craft  S.  et al.  High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001;57 (4) 605- 612
PubMed

Correspondence

CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles